By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
New, nucleotide antivirals to the rescue, including one to fight COVID
Atea Pharmaceuticals is a public (Nasdaq) company developing nucleotide analogs of its own invention to inhibit the growth of “single-strand” (RNA) viruses that cause disease and death. Atea’s lead compound, coded AT-527, is an oral antiviral drug now in global Phase 3 development for COVID indications by Atea and its partner, Roche. An AT-527 phase 2 trial for the treatment of Hepatitis C (HCV) in combination with a potent NS5A inhibitor will restart later this year. Atea also has AT-752 in a Phase 1 trial for Dengue fever. In discovery, it has AT-889 and other candidates targeting respiratory syncytial virus (RSV).